Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target ...
CAMBRIDGE/LEIDEN - ProQR Therapeutics N.V. (NASDAQ:PRQR), a clinical-stage biotech with a market capitalization of approximately $228 million, announced initial safety and pharmacokinetic data from ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results